.Focus On: Industry Declaration on Combating Antimicrobial Resistance (AMR)

In January 2016, leading international pharmaceutical, generics, diagnostics and biotechnology companies, as well as key industry bodies, have come together to call on governments and industry to work together in taking collective action against drug-resistant infections, with a joint Declaration launched at the World Economic Forum (WEF) in Davos, Switzerland (to read the press release click here). The Declaration sets out a common set of principles for global action to support antibiotic conservation and the development of new drugs, diagnostics and vaccines. The declaration is composed of two parts:

The Declaration remains a living document. When published in January 2016, the Declaration had been signed by 85 companies and nine industry associations from across the global pharmaceutical, diagnostics and biotechnology industries. The Declaration remains a living document. When published in January 2016, the Declaration had been signed by 85 companies and nine industry associations from across the global pharmaceutical, diagnostics and biotechnology industries. Copyright Shutterstock

1) A call to action for governments

In the Declaration, signatories call on governments to work with them to develop new and alternative market structures that provide more dependable and sustainable market models for antibiotics. These mechanisms are needed to provide appropriate incentives (coupled with safeguards to support antibiotic conservation) for companies to invest in R&D to overcome the formidable technical and scientific challenges of antibiotic discovery and development. These include mechanisms to ensure that, where appropriate, the pricing of antibiotics more adequately reflects the benefits they bring; and novel payment models that reduce the link between the profitability of an antibiotic and the volume sold.

2) A series of commitments from the signatory companies

The Declaration also sets out commitments to further action on drug resistance by its signatories, across three broad areas. They commit to:

  1. Work to reduce the development of antimicrobial resistance.
  2. Invest in R&D that meets global public health needs with new innovative diagnostics and treatments.
  3. Improve access to high-quality antibiotics and ensuring that new ones are available to all.

The Declaration remains a living document. When published in January 2016, the Declaration had been signed by 85 companies and nine industry associations from across the global pharmaceutical, diagnostics and biotechnology industries. As of 1st April 2016, a total of 98 companies and 11 industry associations in 21 countries have added their signatures to it.

Walking the talk

IFPMA's member companies support the efforts made to meet preservation goals, incentivize innovation and ensure sustainable antibiotic treatments are available to address the health challenges of the future:


Join us in conversations around AMR using the hashtags #AntimicrobialResistance, #AntibioticResistance, #AMR, #SuperBugs, #IndustryOnAMR on social media.


More information on how to slow down antimicrobial resistance and boost antibiotic R&D

 

Partnership information

Therapeutic Focus Infectious Diseases

Disease(s) Drug-Resistant Infections (AMR)

Program Type(s) Health System Infrastructure - Training, Prevention Programs - Awareness & Outreach, Research & Development - Development of Treatments, Research & Development - Innovative Funding Mechanisms

Region(s)

Start Date 2016

Anticipated completion date Ongoing